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Abstract
Introduction: Antiretroviral Treatment (ART) has led to an improvement in survival of HIV infected individuals.
Some of them will develop cancer during the course of their infection and will require radiation therapy. HIV positive
cancer patients have presented with adverse side effects of radiotherapy and elevated chromosomal radiosensitivity.
This study investigated if ART has an influence on chromosomal radiosensitivity of HIV positive individuals.
Methods and Materials: Blood samples from 60 HIV positive individuals were in vitro exposed to doses of X-rays
of 0, 2 and 4Gy and chromosomal radiosensitivity was assessed with the micronucleus assay. The micronucleus
assay was also performed on lymphocytes of a group of non HIV-infected health care workers taking prophylactic
post-exposure ART to measure the effect of these ART drugs on chromosomal radiosensitivity without HIV as a
confounding factor.
Results: All HIV patients (those on ART and without ART) had significantly higher radiation induced Micronuclei
(MN) than healthy controls. The MN yields increased in the HIV patients taking ART compared to HIV patients not
on treatment. The evaluation of chromosomal radiosensitivity of health care workers on ART revealed no effects of
ART.
Conclusions: HIV positive individuals show an increased chromosomal radiosensitivity. Antiretroviral treatment
given to HIV positive individuals can lead to enhanced chromosomal radiosensitivity and therefore impose higher
risks for radiotherapy side effects in these patients.
Keywords: Antiretroviral treatment; HIV; Chromosomal
radiosensitivity
Introduction
In 2013, there were 5.6 million people living with Human
Immunodeficiency Virus (HIV) in South Africa [1]. Antiretroviral
Therapy (ART) has led to the improvement in health and survival of
patients with HIV [2]. South Africa has one of the largest ART roll-
outs in the world and in 2013 over 2 million South Africans were on
ART [2]. The 2006 World Health Organisation’s guidelines for
treatment of HIV infection in adults recommended a first-line
regimen of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
combined with one Non-Nucleoside Reverse Transcriptase Inhibitor
(NNRTI) [3]. Due to their cost effectiveness, Stavudine (d4T) and
Zidovudine (AZT) were the most commonly prescribed NRTIs in low
and middle income countries [4], however due its toxicity, the WHO
updated guidelines recommended using Tenofovir (TDF) instead of
d4T in first-line therapy [5]. In 2010 the South African Department of
Health changed it guidelines to recommend TDF+lamivudine (3TC)/
emtricitabine (FTC)+efavirenz (EFV) as first-line therapy for all new
HIV patients and for those on d4T+3TC/FTC+EFV without toxicity to
remain on that regimen [6]. According to the WHO 2013 guidelines
[7] all patients should be switched to the TDF-based regimen and the
transition of patients to a fixed-dose combination one-pill ART
regimen containing TDF+FTC+EFV began in South Africa in 2013
[8].
ART is not only used in treatment of HIV but also in prevention.
ART is administered prophylactically to non-infected persons after
occupational exposure to HIV. A study in Health Care Workers
(HCWs) has shown post-exposure prophylaxis to be protective after
exposure to the HIV virus [9]. With the high incidence of HIV in
South Africa, HCWs face constant risk of being exposed to HIV after
being cut or pricked by sharps during routine patient care. A South
African study showed that 69% of medical interns reported at least 1
percutaneous injury during their year-long internship [10]. The WHO
guidelines recommend a combination of antiretroviral drugs for post-
exposure prophylaxis based on two nucleoside reverse transcriptase
inhibitors [11].
HIV infection is associated with a high risk of developing specific
AIDS-related cancers such as non-Hodgkin lymphoma, Kaposi
sarcoma and cervical cancer [12]. The prolonged survival of HIV
infected individuals, largely owing to improved ART access, has also
led to an increasing incidence of non-AIDS related cancers amongst
these individuals [13,14]. Radiotherapy is a mainstay treatment for
cancers in South Africa where cancer patients, many of which will be
HIV positive, often present with advanced disease due to limited
access to diagnostic centers in rural areas, lack of awareness and lower
standards of healthcare facilities. As South Africa is also a country with
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a prolific radiation industry and many radiation workers, the high
number of HIV infected people and taking ART in the general South
African population is also likely to be reflected in this workforce. The
effect of HIV and ART on chromosomal radiosensitivity can have
important implications for radiation protection in these workers.
A pilot study by Baeyens et al. (2010) has previously shown HIV
positive patients to be more chromosomally radiosensitive than HIV
negative controls [15]. Chromosomal radiosensitivity is increased
vulnerability of cells to the DNA-damaging effects of ionizing
radiation. It can be a result of impaired DNA damage repair.
Associations between clinical response to radiotherapy and
chromosomal radiosensitivity [16,17] and elevated radiotoxicity such
as mucositis and neutropenia has been reported in some HIV patients
receiving radiotherapy for several types of cancers (reviewed in [18]).
As radiotherapy decreases CD4 cell counts [19], HIV positive people
in clinical settings are advised to start ART before undergoing
radiotherapy to minimise the risk of developing AIDS, particularly
when the patient has low CD4 counts.
Since NRTIs and NNRTIs interact with host DNA, it is possible that
they could have an impact on DNA damage repair and affect
chromosomal radiosensitivity. AZT, 3TC and TDF have been shown
to inhibit cell growth [20], to interfere with cell cycle arrest, induce cell
death by apoptosis and inhibit telomerase activity [21-24]. Conflicting
studies have shown AZT to act as a radioprotector or a radiosensitizer
[25,26].
Chromosomal radiosensitivity can be tested through a variety of
cytogenetic assays. A reliable and well-established method is the
cytokinesis-block micronucleus assay (MN assay) that is commonly
used in biological dosimetry and chromosomal radiosensitivity
studies. Micronuclei (MN) are small nuclei that form in the cytoplasm
when chromosomes or chromosome fragments are not incorporated
into the daughter nuclei subsequent to cell division [27]. MN reflect
the amount of DNA damage and DNA damage repair after exposure
to radiation. The MN assay can be performed on lymphocytes, which
are easily obtainable via venipuncture. The micronucleus assay is also
considered a sensitive method to evaluate the cytotoxic potential of an
active agent. The nucleoside reverse transcriptase inhibitors AZT, 3TC
and d4T have been shown to produce an increase in MN in human
lymphocyte cultures [28-30].
In this study the micronucleus assay on the lymphocytes of HIV
patients not taking ART and of HIV patients on one of the 2 most
commonly administered ART regimens in South Africa (d4T+3TC
+EFV and TDF+3TC+EFV) was performed to assess the effect of HIV
and these drugs on chromosomal radiosensitivity. The micronucleus
assay on the lymphocytes of a group of non HIV-infected health care
workers taking prophylactic post-exposure ART was also performed to
measure the effect of these ART drugs on chromosomal
radiosensitivity without HIV as a confounding factor.
Materials and Methods
Study population
Heparinised blood samples from 60 HIV positive individuals were
obtained from the Themba Lethu HIV unit at the Helen Joseph
Hospital in Johannesburg, South Africa. Twenty participants were
HIV positive but not taking any ART medication. Twenty participants
were on the d4T+3TC+EFV (30mg/150mg/600mg) regimen and
twenty participants were taking the TDF+3TC+EFV (300mg/150mg/
600mg) regimen. HIV patients were on ART for at least 6 months.
Blood samples of 20 HIV negative healthy individuals, age-matched
with HIV positive individuals, were included as controls. These were
staff members and students from Charlotte Maxeke Johannesburg
Academic hospital (CMJAH) where the study was undertaken.
Population characteristics and treatment data are shown in Table 1.
The CD4 counts, measured on the same day as the MN assay, were
extracted from clinical records.
HIV ART HIV ART
Healthy individuals HIV without ART D4T/3TC/EFV TDF/3TC/EFV Health care workers
Gender
female/male 14/6 15/5 13/7 18/2 8/2
Age
mean ± SD 30 ± 7 36 ± 10 37 ± 7 41 ± 6 31 ± 11
range (min-max) 23 - 52 18 - 55 29 - 54 34 - 53 22 - 56
CD4 cell counts
mean ± SD 480 ± 164 ** 623 ± 240 649 ± 204
range (500 - 1200)* 268 - 858 202 - 1081 302 - 933
Duration of ART (months)
mean ± SD 51 ± 26 51 ± 28 1
range 13 - 100 6 - 99
* normal range of CD4 counts in a healthy population
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** significantly lower than HIV ART groups
Table 1: Patient Characteristics.
For the second part of the study, heparinised blood samples of 10
health care workers on post-exposure ART prophylaxis were collected
from CMJAH. All the HCWs were taking a combination of 2 NRTIs
(300mg AZT + 150mg 3TC or 200mg FTC + 300mg TDF) for 28 days.
Blood samples of these HCWs were taken at 3 time points: The first
was the day of the needle-stick or sharps injury, just before starting
prophylaxis treatment (T1); the second was 3-4 weeks after T1, after
completion of the ART course of medication (T2); the third was
between 3 and 4 months after T1 (T3). All blood donors signed
informed consent and the study was approved by the Human Research
Ethics Committee, University of Witwatersrand, Johannesburg, South
Africa (M110361 and M120270).
Micronucleus assay
The micronucleus assay was performed as described by Baeyens et
al. [15]. In vitro chromosomal radiosensitivity was measured by
scoring MN in lymphocytes irradiated with doses of 2 Gray (Gy) and 4
Gy. A 2 Gy dose is frequently used in radiotherapy fractionation
schedules. A 0 Gy dose was used as a sham-irradiated control
(spontaneous MN) and also allowed us to examine the cytotoxic effect
of ART on lymphocytes without irradiation. Lymphocyte cultures
were set up by adding 0.5 ml blood to 4.5 ml of prewarmed RPMI
(Roswell Park Memorial Institute) 1640 (BioWhittaker, Walkersville,
USA) that was supplemented with 13% foetal bovine serum (Gibco-
Invitrogen, New York, USA) and 0.01% antibiotics (50 U/ml penicillin
and 50 mg/ml streptomycin; Gibco-Invitrogen). The irradiations were
done in the Radiation Oncology Unit at CMJAH. Culture flasks were
placed in a Phantom-water tank at room temperature and irradiated
with X-rays using a 6 MV photon beam from a medical linear
accelerator (Siemens Healthcare, Erlangen, Germany). The distance
from the culture flasks to the radiation source was 100 cm at an angle
of 90 degrees. The field size at the depth of the sample was 10X10 cm
and the dose rate was approximately 1.33 Gy/min. For each dose
point, 2 co-cultures were set up. Subsequent to irradiation,
lymphocytes were stimulated by adding 100 µl of
phytohaemagglutinin (stock solution 1mg/ml, Sigma-Aldrich, St
Louis, MO, USA). To block cytokinesis, 20 µl cytochalasin B (stock
solution of 1.5mg/ml, Sigma-Aldrich) was added to the cultures at
23hrs. Cells were harvested 70hrs after stimulation using a cold (4°C)
hypotonic shock with 7ml 0.075M KCl (Merck, Darmstadt, Germany).
This was followed by fixation in methanol: acetic acid: Ringer (0.9%
NaCl) solution (4:1:5) (Merck) at 4°C overnight. Thereafter cells were
fixed another three times with methanol: acetic acid (4:1) (Merck).
Cell suspensions were dropped on slides and stained for 1 minute with
acridine orange stain (10µg/ml) (Sigma-Aldrich, St Louis, MO, USA)
and immersed for 1 min in acridine orange buffer (Sigma-Aldrich, St
Louis, MO, USA). Duplicate slides were made of each sample, coded
and scored blindly by 2 experienced scorers using a Zeiss Axioskop
fluorescent microscope (400X) (Carl Zeiss, Gottingen, Germany). At
least 500 binucleated cells (BN) were scored per slide, according to the
criteria of Fenech [31]. The results of both scorers were combined and
normalised to 1000 BN. The number of mononucleated (N1),
binucleated (N2), trinucleated (N3) and polynucleated (N4) cells per
slide was scored and the nuclear division index (NDI) was calculated
according to the formula: NDI= (N1+2N2+3N3+4N4)/Ntot where Ntot
is the total number of cells per slide counted (Ntot = 500 cells).
Statistical analysis
Statistical analysis was performed with Graph Pad Prism 6. The
non-parametric Mann-whitney test was used to compare means of
MN counts and NDI values between the different population groups.
For HCWs, differences between MN counts at different time points
were tested for significance with the non-parametric Wilcoxon test.
Significance was set at p<0.05.
Results
Effects of ART on chromosomal radiosensitivity in HIV
positive individuals
The results of the MN assay for the four groups (HIV patients not
on treatment, HIV individuals on ART regimens TDF+3TC+EFV and
D4T+3TC+EFV and healthy controls) are shown in Table 2. In
unirradiated cells (0Gy), there were no significant differences in
spontaneous mean MN yields between the groups. Radiation-induced
MN yields were calculated by subtracting spontaneous MN yields from
MN yields in irradiated cells. The radiation-induced MN yields were
significantly higher in patients (both regimens and without ART)
compared to healthy controls at both 2Gy and 4Gy. Although both
patient groups on ART had higher MN yields than HIV patients not
on treatment, patients on TDF+3TC+EFV had the highest average
MN yields, the increase being significant at 4Gy. The HIV patients
without ART had significantly lower CD4 counts compared to those
on ART. There was no correlation between CD4 counts, time on ART
treatment and MN yields (data not shown). The mean NDI values for
the unirradiated (0Gy) cultures were similar for all the groups, but the
mean NDI for the irradiated cultures (2Gy and 4Gy) were significantly
lower in the patients on ART compared to the HIV patients without
ART and the healthy controls (p <0.005).







0Gy N 20 20 19 20
Mean 14 14 12 10
SD 6.4 6.0 7.4 5.8
2Gy
induced
N 20 19 18 18
Mean 300 355 368 386
SD 58.3 71.4 58.9 58.2
p values vs controls 0.0125 0.001 <0.0001
p values vs HIV
without ART
0.5414 0.1531
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4Gy
induced
N 20 18 16 19
Mean 842 969 1018 1076
SD 151.6 134.6 157.8 146.6
p values vs controls 0.0098 0.0017 <0.0001
p values vs HIV
without ART
0.3407 0.0277
Table 2: MN yields (per 1000BN) for the HIV positive individuals not
taking ART, HIV positive individuals taking 2 different ART regimes
and healthy individuals.
Effect of ART on chromosomal radiosensitivity of health
care workers
The MN yields for the 10 health care workers on prophylactic ART
before starting ART (T1), at the completion of ART (T2), or 3-4
months after the completion of ART (T3) are shown in Table 3. There
were no significant differences between the mean spontaneous and
radiation-induced MN yields at the 3 measured time points.
T1 T2 T3
0 Gy Mean 10.3 13.4 10.9
SD 3.5 5.2 4.4
p values 0.234 0.836
2 Gy Mean 307.7 297.1 296.1
SD 90.9 78.8 82.7
p values 0.625 0.547
4Gy Mean 826.2 842.0 834.0
SD 146.2 206.0 192.2
p values 0.943 0.844
Table 3: Comparison of MN yields (per 1000BN) of health care
workers taking prophylactic post-exposure ART before starting ART
(T1), after 3-4 weeks on ART (T2) and 3 months after ART (T3).
Discussion
The present pilot study investigated if HIV and antiretroviral
medication has an influence on chromosomal radiosensitivity. This is
one of the first studies looking at the effects of ART on radiosensitivity
in HIV infected individuals and is potentially very important for many
cancer patients and radiation workers in South Africa exposed to
radiation that will be HIV positive and on ART. Since NRTIs interact
with host DNA, inhibit mammalian DNA polymerases and affect the
cell cycle [21], it is possible that they have an impact on DNA damage
repair and affect chromosomal radiosensitivity. Some studies have
shown antiretroviral drugs to be radioprotective while others have
suggested a radiosensitising effect [25,26]. For the first part of this
study we investigated the chromosomal radiosensitivity of HIV
patients not on ART, HIV patients on two common ART regimens
(d4T+3TC+EFV and TDF+3TC+EFV) and compared it to healthy
uninfected controls.
Micronuclei are considered a biomarker of cytotoxicity. In
unirradiated cells no difference in MN yields between the four groups
was detected, suggesting no cytotoxicity of the ART in-vivo. These
findings are in agreement with those of Robbins et al. [32] who
detected no biologically relevant changes in lymphocyte chromosomal
aberrations in 26 HIV positive patients on combinations of ART
(AZT, 3TC, d4T) across a number of time points. On the contrary,
Shafik et al. (1991) [33] observed a high increase in chromosomal
aberrations in AIDS patients treated with AZT and suggested that
AZT induces genetic damage in lymphocytes of AIDS patients. None
of the studied HIV positive patients were taking AZT, so this could
explain the discrepancy between Shafik et al. (1991) [33] and the
results presented here. Proliferation rates of lymphocytes from HIV
infected individuals are known to be higher than HIV uninfected
individuals [34], but this was not reflected in the NDI’s calculated in
this study. In lymphocytes irradiated with 2 and 4Gy, a difference in
MN between the groups was noted that points to differences in
chromosomal radiosensitivity. All HIV patients (those on ART and
without ART) had significantly higher MN than healthy controls. This
confirms earlier findings of Baeyens et al. [15]. The patients on the
ART regimens had higher MN yields than HIV patients not on ART,
with the TDF+3TC+EFV regimen presenting with significantly higher
radiation-induced MN at 4Gy. The results suggest that substitution of
d4T with TDF in the ART regimen of HIV patients leads to an
enhanced chromosomal radiosensitivity. Cytotoxicity studies on TDF
in vitro have been conflicting. Cihlar et al. (2002) [35] and Hecht et al.
(2013) [36] have shown TDF to exhibit low cytotoxicity in various cell
types, while a study by Bruning et al. [23] indicated that TDF induced
DNA damage, reduced cell viability and induced cell cycle
disturbances leading to apoptosis in cancer cells. This last statement
could mean that TDF may be beneficial in radiosensitising tumour
cells in HIV positive individuals, but its effect on normal tissue
radiotoxicity, seen in the lymphocytes in this study, may be adverse.
The significantly higher MN yields at 4Gy in the TDF group could
reflect the un/misrepaired, severe DNA damage caused by the
combination of HIV-infection, TDF and ionising radiation. Since
studies have shown an association between clinical response to
radiotherapy and chromosomal radiosensitivity [16,17], the effect of
ART, especially TDF, on radiotoxicity requires further investigation.
For the second part of the study, we investigated the chromosomal
radiosensitivity of 10 non-HIV-infected South African HCWs on the
post-exposure prophylaxis ART to determine the effect of ART on
chromosomal radiosensitivity without HIV as a confounding factor.
All participants were on an ART regimen including two NRTIs. In
unirradiated lymphocytes of these donors, no differences were
detected in average MN yields before, during or after ART. The
increase in chromosomal aberrations in AIDS patients taking AZT,
seen in the study of Shafik et al. [33], was not noted in the HCWs
taking AZT. The different results between both studies could suggest
that not only AZT but the combination of HIV infection and AZT lead
to increased chromosomal damage. The in vitro genotoxicity effects of
AZT and 3TC seen in studies of Stern et al. [29], Lourenco et al. [28],
and Gonzalez Cid et al. [30] were not confirmed in the current study.
The fact that in these studies, ART was added in high concentrations
for short terms in vitro to cell cultures, while in this study the ART was
administered in vivo over a longer period, could explain the observed
difference. No changes were noted in average radiation-induced MN
yields of the HCWs at the different time points. Jagetia and Aruna
[25], found that administration of AZT to Hela cells before exposure
to different doses of γ-radiation resulted in a significant elevation in
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the yield of MN. This was in contrast to Copaceanu et al. [26] who
suggested radioprotection of AZT in Hela cell lines exposed to
irradiation in-vitro. Several publications demonstrated that AZT and
3TC alter cell cycle kinetics and increase the proportion of cells in S
phase [21,22]. Radiosensitivity of cells differs according to cell type
and phase of the cell cycle the cells are in at the time of irradiation
[37]. In both studies of Jagetia and Aruna [25] and Copaceanu et al.
[26] irradiations were performed on rapidly-dividing Hela cell lines,
while in the current study, lymphocytes were irradiated in the G0
phase of the cell cycle.
Following from the MN data on HCWs taking ART, we could not
support that either AZT or 3TC have a radiosensitising or
radioprotective effect on lymphocytes of healthy individuals. The fact
that the increased chromosomal radiosensitivity, seen in HIV positive
individuals on ART was not observed in the lymphocytes of HCWs on
ART could be due to the following reasons: 1) The duration of the
ART was different (more than 6 months for HIV positive patients
versus 3-4 weeks in HCWs). 2) It is the ART and the HIV virus in
combination with the radiation that led to increased MN yields in
HIV-infected patients on ART. 3) It is different ART compounds or
the combinations (d4T, TDF and EFV versus AZT) exerting different
effects in the cells in response to ionizing radiation.
The results of this study suggest that HIV and certain recent ART
(TDF+3TC+EFV) given to HIV positive individuals can lead to
enhanced lymphocyte chromosomal radiosensitivity and therefore
may impose higher risks for radiation-induced normal tissue
complications in these patients. Further investigation of the different
compounds of ART in combination with ionizing radiation is
warranted, as HIV positive cancer patients undergoing radiotherapy
and HIV positive radiation workers may potentially benefit from
having their ART regimens altered according to the radiomodulatory
effects of the various drugs.
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